Researchers Improve Allergy Testing to Detect Antibodies Behind Reactions

Allergies can range from mild symptoms to life-threatening anaphylaxis, yet routine blood tests often fail to explain which patients truly need to avoid specific foods. Current approaches typically quantify allergen-specific IgE, but the presence of IgE does not necessarily mean it can actively trigger reactions in the body. This gap between laboratory results and clinical risk complicates diagnosis and can lead to unnecessary dietary restrictions. A new study from Japan aims to narrow that disconnect by measuring the functional potential of allergen-specific IgE rather than simply its abundance.

The immune mechanism at the center of allergy involves IgE binding to FcεRI receptors on effector cells such as mast cells. For symptoms to occur, allergens must cross-link multiple FcεRI-bound IgE molecules, initiating downstream signaling that culminates in allergic inflammation. Conventional assays can miss this step, classifying some individuals as sensitized even when their IgE fails to produce clinically relevant responses.

To overcome that limitation, researchers adapted the AlphaCL method—originally designed for IgE cross-linking detection in chronic urticaria—into a more practical functional test for food allergy sera. The improved protocol addresses a key technical obstacle: interference from serum components that can blunt IgE detection signals. By using modified allergens to remove interfering serum factors before readout, the assay retains substantially more signal than the original configuration.

Performance evaluation was conducted under serum-containing conditions that mimic real clinical samples. The improved AlphaCL assay preserved 66% of signal compared with serum-free measurements, whereas the conventional approach retained only 3.3%. This sensitivity boost supports the method’s ability to detect activity relevant to FcεRI cross-linking rather than passive IgE presence.

The team then tested patient sera against representative food allergens, including egg, wheat, and milk. Among pediatric patients who had tested positive on oral food challenges, the improved method detected functional allergen-specific IgE in 28 of 30 cases (93.3%). Importantly, the method’s design suggests it can be adapted to multiple allergen targets, potentially broadening its clinical utility.

As a functional “lock-and-key” readout, the assay distinguishes IgE that can actually “unlock” FcεRI-mediated activation from IgE that merely binds in measurable quantities. The authors emphasize that their analyses focused on oral food challenge–positive cohorts and involved limited case numbers, setting the stage for larger studies to confirm clinical accuracy across broader populations and allergen types.

The work was published in Methods (May 10, 2026). It was supported in part by the Japan Society for the Promotion of Science (JSPS KAKENHI, grant 24 K08809). If validated in future trials, the improved AlphaCL approach could offer a safer and more informative alternative to riskier functional testing and reduce diagnostic uncertainty in pediatric food allergy care.